We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current SLNCF market cap is 753.76M. The company's latest EPS is GBP -0.3760 and P/E is -18.62.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 0 | 244k | 5.48M | 12.42M | 17.5M |
| Operating Income | -20.57M | -22.73M | -32.48M | -45.81M | -48.59M |
| Net Income | -18.41M | -19.58M | -32.55M | -39.41M | -40.49M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 38.89M | 46.08M | 85.97M | 96.19M | 107.5M |
| Total Liabilities | 3.83M | 25.17M | 76.91M | 87.67M | 85.43M |
| Total Equity | 35.06M | 20.91M | 9.06M | 8.53M | 22.07M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -16.76M | 1.73M | -10.78M | 6.81M | -45.46M |
| Investing | -4.83M | -15.02M | 9.62M | 8.68M | -16.54M |
| Financing | 341k | 5.27M | 15.43M | 30.71M | 43.05M |
| Market Cap | 753.76M |
| Price to Earnings Ratio | -18.62 |
| Price to Sales Ratio | 43.08 |
| Price to Cash Ratio | 13.75 |
| Price to Book Ratio | 34.15 |
| Dividend Yield | - |
| Shares Outstanding | 107.68M |
| Average Volume (1 week) | 500 |
| Average Volume (1 Month) | 648 |
| 52 Week Change | 430.26% |
| 52 Week High | 10.90 |
| 52 Week Low | 0.60 |
| Spread (Intraday) | 5.18 (46.29%) |
| Company Name | Silence Therapeutics PLC (PK) |
| Address |
27 eastcastle street london W1W 8DH |
| Website | https://www.silence-therapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
